{"name":"Cirius Therapeutics, Inc.","slug":"cirius-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MSDC-0602K","genericName":"MSDC-0602K","slug":"msdc-0602k","indication":"Type 2 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"MSDC-0602K","genericName":"MSDC-0602K","slug":"msdc-0602k","phase":"phase_3","mechanism":"MSDC-0602K is a thiazolidinedione-class insulin sensitizer that activates mitochondrial pyruvate carrier (MPC) to improve insulin sensitivity and glucose metabolism.","indications":["Type 2 diabetes mellitus","Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOaUdzN0lLVl9Cb0pHWGx2QjZNakVIWHVjdTEzNUNUVzVwRFhVWERQMVlBd2JuWjVFZ3JBR3Y1MjVRUDhiZnZwb3k5Z3RFcWk2anB2NlhIQjlmaTE3andENFRxbUdiZzNiU3VmM3pwV1hQNXhNejVpTG5LVDhPZmpZbkxVMDBBT0NZcDBOQm9oT0tYM3pmVGo1dEZ3enhJRnlpODhoakN2N1VPMFJqN3dPZ3RHZzdKM2pmMzd2bEVJUnMxSFFCN2NfWktSZkxSOFFpNUJNRQ?oc=5","date":"2026-01-05","type":"pipeline","source":"Harvard Business School","summary":"Q&A: A Blavatnik Fellow’s Journey: Ying Kai Chan on Vision Science, Innovation, and Cirrus Therapeutics - Harvard Business School","headline":"Q&A: A Blavatnik Fellow’s Journey: Ying Kai Chan on Vision Science, Innovation, and Cirrus Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxOU0RLZ2FkTzgtVUItNFJJbmJuRzBwSE1MR3lBcm81cExHTi0tMjRWYWhIN0IyVVN4SUNrek4tNjhmSGVxMktxV0lIck5pTWZVb2ZjeXdfNHMxM1lJV3Vyc3A2WUN3VjhxUDc0MmJtc3Z5QmhXRW11dmRCejZXbmxKTkNKSUJIcUgxbm80Qjh3b3BVbkt4QlhKN2tId1FpMmhDcEZJLWs5b281N3FBVWVpVjgwcmdjc1Q5bGt1THZwV3lZUFp4TnRoeGJJQ2lURVVJb2hMUlNHdDdsYXJYQ0lhWjh3YUxtUWZIY1pFd3UxUzMydHJrUmhUaTZwZ0pRMFdNOGRoeVluUTNCVFc4bHFkbllzMno?oc=5","date":"2025-12-09","type":"trial","source":"prnewswire.com","summary":"Cirius Therapeutics to Highlight Cardiometabolic Benefits of CIR-0602K at Global Cardiovascular Clinical Trialists (CVCT) Forum 2025 - prnewswire.com","headline":"Cirius Therapeutics to Highlight Cardiometabolic Benefits of CIR-0602K at Global Cardiovascular Clinical Trialists (CVCT","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNNlF3bFlacXN3UWxzMUxXcTdCcGQySVh0b1ZoREZ4aFdoczMyUDhjUF9ZUmgya3RXeTUxeGhJcl9reXU5QjhNUU9nZ1ZOVE94aFNHdEh0NWNZbVVVN3JXeUx0S2FxQW1hd2FQSmprZXZUdGY1Mjh2MzkwUndkQW1FRnZ0aWZnN1RsQnNSRHZMWDhUM0FyZXpyNkN0YzJGQjBIQzRmc3RyQUJ6WkpVRzB3S3dTa0o1M1ZvaXVPbDh1dWp3Njh0OUFINU94LS1FakNUVy0zdDVVUndheFZsVl9rd2dyY1Vud0ZYUlk0X3pKeXVFekVRUkQw?oc=5","date":"2025-11-04","type":"trial","source":"prnewswire.com","summary":"CIR-0602K Demonstrates Synergistic Metabolic Benefit with Tirzepatide: New Data Presented at ObesityWeek 2025 - prnewswire.com","headline":"CIR-0602K Demonstrates Synergistic Metabolic Benefit with Tirzepatide: New Data Presented at ObesityWeek 2025","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNlhQQ3pXX0FwYURHc2R3Rl9SdWZXSzFFZVRoR09RWnl4WnBUUnRVMlpYeEJZdFROMFNwYU5GUEhSRExaRzZtaUJLSVd2N1hOUTNTRERMelhOb3ZXRVY3NVd5WUJXWVhxamMxMVE3akF0UDA5VlRkTURNbldWMVd0WFQydnAxbVktUzczUFh1dS1BYV9Na0ZfNkVhdEctYW5GZDZPR1YwZUFPUkJzWHBORGJqSFhvU1pIR19iRTlzcEctR2M?oc=5","date":"2025-10-09","type":"pipeline","source":"prnewswire.com","summary":"Cirius Therapeutics to Participate in Upcoming Healthcare Conferences - prnewswire.com","headline":"Cirius Therapeutics to Participate in Upcoming Healthcare Conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNekVJaVFIREJIMjhLejA5UkVSZ21FX2h3c0g5UDlyQ3F6WGxZTDljdEZJQU1hZUtJYWU4a3p4UnNlbHE4UG9BbGZSdS1IZEQyWksxdlhLemt4bG5keE1SQjZKR21wcnk0eHFjQ1RKMDNkM2ZQUU5zaFRZQlRfanpURDFmeG1CVmtHUmdoY0dxTFpvZTJVc1E?oc=5","date":"2025-10-09","type":"deal","source":"seekingalpha.com","summary":"Novo Nordisk's Akero Deal: Panic Buy Or Wise Decision? Here's My Take (NYSE:NVO) - seekingalpha.com","headline":"Novo Nordisk's Akero Deal: Panic Buy Or Wise Decision? Here's My Take (NYSE:NVO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBLZWQzeXNEWkZjelVIemxBdS1vdjJzWGhqY1pTRlRZcmY5Tjk5d3NzbU93TU1Pb2xLVS1fOE9tN1dYcnhDaUlYZ1pfQVBOSUxuVl93aGdVc1NhS3VWQ0Jocw?oc=5","date":"2025-10-03","type":"pipeline","source":"The Pharma Letter","summary":"Cirrus Therapeutics - The Pharma Letter","headline":"Cirrus Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPbnRrd2tWeUVrWjlGRGJYSDZHUnFfWkFUdTluZlNielVMdmgzNmdkQk9RT3gtUzVXbWgybi1hMnZ0bGNDVjA1dG9YdWMwaVlHd1RpUklpYTJlb3MxY3gza1QtV2JDMnRMem11N3IxYmZySnNJdTlXdnN3NW9aclJMOENDU0QxM3NUbnVYOTBiSHV2NjhkdEFLWV9paF9hY0pQVXFrdQ?oc=5","date":"2025-10-03","type":"pipeline","source":"The Pharma Letter","summary":"Cirrus launches with $11m to push gene therapy for dry AMD - The Pharma Letter","headline":"Cirrus launches with $11m to push gene therapy for dry AMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFB3dkkwYkdfcXdTMVNJdGVFVE5wX2NGT29WQjA5MExmeVZoLXZ5VG5lMi03Wnp0UHg4OTBZSi1rYTBJNzUyZno4X0tEQkRmRUl2ekJv?oc=5","date":"2025-10-02","type":"pipeline","source":"FirstWord Pharma","summary":"Cirrus nabs $11M on quest for a gene therapy solution to AMD - FirstWord Pharma","headline":"Cirrus nabs $11M on quest for a gene therapy solution to AMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPMVFhUm04TWRMVjUxNzlQVWE2ZVpNMEFpcXF3cGg3MEVuZDhSUU9KbUJreFFra2pXS1RYdVdHNWxpT1JFVjF6WUsyeWlYRVNSOXZNakNhSVVBV29wcmFzMmd3UENnTFVnUVFkb2R0SEQyUWdPc0E5SFRHSjhxOEEtVEJxM0lxbW4tXzQydlFiQ3BxWS1j?oc=5","date":"2025-10-02","type":"pipeline","source":"The Business Journals","summary":"Polaris-backed gene therapy startup launches with focus on eye disease - The Business Journals","headline":"Polaris-backed gene therapy startup launches with focus on eye disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPN0RqLWFxMDNUVC1nWUhBY0xTc0dWcWNTN1lrbWhkLXlJVG1TQ1pZTkJiZjd3bUdiOFFOT0dSN0hvSkJwM1c5LWxQa05xWGV6Q0pvMzd2anhkWXpyYS16RW1GcS10WjR3VE5zZzFiQTgyT1Y3S1czYkN0SEFuQ01ONVJhVDllTl84NDdpTG4tSFhOYzNTeFM1eGxldmhOZGs4UExDQ2Jvc1p1YkJWUllV?oc=5","date":"2025-08-14","type":"deal","source":"seekingalpha.com","summary":"Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating - seekingalpha.com","headline":"Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQQU9oem40R1BZVjBBZ1BJdW9tM0ZralJudXFnMXU4U192TmZfdVhXSDJyN04yUDZKNDMwNkEta1UwdVA3RzdCekNxNElXVmFtR08tUk1fWnRtZEIyZzZDSkdTVTlEeUlOT3VnelZPRlc4RTZEVUwtM3VYSU1BRk5Tc21ZTS1WZ3kzUkpTN0VLWDRCYVNpNW5VN19iaG5mX3k4NU5JejFlS3JGTlgzT3I0TUVnRnotNWY5bnMwcDE2dTVib3ZVSnFGbU42QThWSkR6ZzFMdE56dUxHa1lGYi1aU01HRnotQVJtMm1UNEZRX0YtOXhGandyWg?oc=5","date":"2025-06-20","type":"trial","source":"prnewswire.com","summary":"Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide - prnewswire.com","headline":"Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOdEFKWGZBTDNkaEg0SHFZRkVmRm5VMF9rS014M2k1Ti1SUmNYc042dEJab3o4ckRuaWozM1pxRXJqYk04azFjU2x6TDB6d2JzUHNZZjFwLUNtTUFGcHMyakl0Vm44U2l3Wlg0N3RfLURKNGtES1VpY1MwUGEzMW5MTGpQNTlmRVdQeXc?oc=5","date":"2017-12-05","type":"pipeline","source":"BioSpace","summary":"What You Need to Know About Cirius Therapeutics - BioSpace","headline":"What You Need to Know About Cirius Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}